Physician

Abdo S Haddad, MD

According to 2025 Medicare claims, Abdo Haddad, MD (NPI: 1467480871) practices hematology/oncology in the Cleveland, OH market, with the plurality of this provider's patient population coming from Cuyahoga, OH. This provider's primary affiliated billing organization is THE CLEVELAND CLINIC FOUNDATION (NPI: 1679525919; TIN: 340714585) and primary practice location at 44111-5605. Haddad is affiliated with the Cleveland Clinic Medicare ACO, LLC (ACO ID: A2729), participating under the MSSP model.

Haddad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 259 traditional Medicare patients, billed 959 HCPCS/CPT codes, and received $48,440 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,067 prescription claims across 208 beneficiaries totaling $3,316,385 in drug costs, led by Lenalidomide (Lenalidomide). 2023 DME data shows 40 claims. Open Payments data shows 2 records totaling $200. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $51,909 and ending at $48,440. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,293,846 to $3,316,385. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,561 to $518.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	280	922	$51,909
2016	351	1,373	$100,722
2017	343	1,093	$78,584
2018	326	983	$64,969
2019	332	975	$75,241
2020	346	807	$55,229
2021	295	727	$55,446
2022	265	603	$42,859
2023	320	807	$60,321
2024	259	959	$48,440

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	147	1,021	$1,293,846
2016	163	1,077	$1,694,934
2017	162	1,042	$1,792,823
2018	181	1,117	$2,167,905
2019	190	1,096	$2,701,365
2020	224	1,463	$3,545,036
2021	202	1,325	$3,530,660
2022	190	1,148	$3,164,926
2023	193	1,072	$2,463,187
2024	208	1,067	$3,316,385

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	156	$46,982
2016	N/R	93	$6,352
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	53	$4,417
2021	N/R	42	$4,382
2022	N/R	76	$2,383
2023	N/R	40	$11,309
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	46	81	$100
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	33	40	$85
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	153	305	$69
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	91	103	$45
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	188	345	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	39	1,092	$561,015
Kisqali	Ribociclib Succinate	27	742	$424,592
Revlimid	Lenalidomide	29	812	$415,672
Brukinsa	Zanubrutinib	30	900	$314,746
Tagrisso	Osimertinib Mesylate	12	360	$204,556

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$200	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdo S. Haddad, MD?

Tedicare shows public-source Medicare data for Abdo S. Haddad, MD (NPI 1467480871), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdo S. Haddad, MD have ACO affiliation data?

Abdo S. Haddad, MD is shown with ACO affiliation data for Cleveland Clinic Medicare ACO, LLC (MSSP, ACO ID A2729).

What billing organization is linked to Abdo S. Haddad, MD?

Abdo S. Haddad, MD is linked to THE CLEVELAND CLINIC FOUNDATION (billing NPI 1679525919) in the available physician profile data.

Does Abdo S. Haddad, MD have Open Payments data?

Abdo S. Haddad, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.